tomorrowread
Mabwell clears Brazilian GMP inspection for denosumab biosimilars
pharma·Short term·▼ -3%

Mabwell will use the Brazil GMP win to accelerate denosumab filings across PIC/S markets.

Regulatory wins like this can open doors in large markets and strengthen a biosimilar company’s international credibility.

AI reasoning

Regulatory wins like this can open doors in large markets and strengthen a biosimilar company’s international credibility.

Curated summary

Mabwell said its subsidiary T-mab passed Brazil’s ANVISA GMP on-site inspection for denosumab biosimilars 9MW0311 and 9MW0321. The company says this is its second GMP certification from a PIC/S-member authority, after Jordan. Mabwell has already filed denosumab applications in eight countries, including Brazil, and has marketing approval in Pakistan.

Supporting evidence

Source news

Mabwell clears Brazilian GMP inspection for denosumab biosimilars

The company says ANVISA passed its T-mab subsidiary on-site, marking a second PIC/S-member GMP certification and widening its global regulatory runway.

Guru Focus·7h ago
Read full article at Guru Focus